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ABSTRACT
Isolates of Pseudomonas aeruginosa (n = 208) were collected from an 810-bed hospital in Connecticut,
USA. A model employing the pharmacokinetic properties of meropenem, susceptibility results and
Monte Carlo simulation was used to analyse four different dosing regimens of meropenem at
pharmacodynamic endpoints. Cumulative fraction of response (CFR) was assessed at bacteriostatic and
bactericidal endpoints for the entire population of isolates, as well as for isolates from principal
anatomical sites. CFR was also evaluated at endpoints shown to suppress emergence of resistance in
‘susceptible’ P. aeruginosa with either monotherapy or combination therapy. The bacteriostatic ⁄ bacte-
ricidal CFR of meropenem 1 g every 8 h (q8h), 2 g q8h, 1 g q8h infused over 3 h (3-h INF), and 2 g q8h
3-h INF were 76% ⁄ 73%, 80% ⁄ 76%, 77% ⁄ 75% and 79% ⁄ 78%, respectively. At the monotherapeutic
suppressive endpoint, CFRs against susceptible isolates were 21%, 35%, 32% and 50%, respectively.
When combination therapy with an aminoglycoside was simulated, the CFRs for the same regimens
were 50%, 64%, 65% and 79%, respectively. Bactericidal CFRs for all regimens against wound isolates
were signiﬁcantly higher (p <0.03 for each regimen) than CFRs for the entire population. Meropenem
2 g q8h with a 3-h infusion in combination with an aminoglycoside provides the greatest likelihood of
P. aeruginosa coverage, and may help to prevent development of resistance, although local MIC data are
essential to inform therapeutic decisions.
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INTRODUCTION
Pseudomonas aeruginosa is a leading cause of
nosocomial infections worldwide. This Gram-
negative organism possesses inherent resistance
to many classes of antibiotics, as well as the
ability to acquire resistance to compounds used
commonly for therapeutic purposes. Severe
infections caused by P. aeruginosa are associated
with a high mortality rate, regardless of whether
appropriate antimicrobial therapy is used [1,2].
The carbapenems are popular options for the
treatment of mixed bacterial infections and for
infections with aerobic Gram-negative bacteria
that are unlikely to be susceptible to other
b-lactam agents. However, as is noted for all
antimicrobial therapies, indiscriminate use of
these agents will probably promote further
increases in resistance rates [3]. P. aeruginosa can
develop mutational resistance to all the ‘anti-
pseudomonal’ penicillins, cephalosporins, carb-
apenems, aminoglycosides and ﬂuoroquinolones
that are currently available [4]. No potent anti-
pseudomonal drugs have been developed during
the last decade, and the carbapenems are gener-
ally the most active anti-pseudomonal agents
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available. However, resistance to carbapenems
has begun to develop [5–7]. Resistance mecha-
nisms include mechanisms resulting from
spontaneous mutation, e.g., up-regulation of
MexA–MexB–OprM, loss of protein OprD and
derepressed AmpC b-lactamase, and plasmid-
encoded mechanisms, including the production of
metallo-b-lactamases.
Antibiograms at Hartford Hospital, CT, USA
have revealed that susceptibility of P. aeruginosa
to most antimicrobial agents has been declining;
this is an issue of concern, as P. aeruginosa is a
cause of many serious nosocomial infections,
including respiratory tract infections, intra-
abdominal infections, and infections of skin
and skin structures. Thus, a recent investigation
of ventilator-associated pneumonia at Hartford
Hospital revealed high rates of mortality (35%)
and high rates of infection with P. aeruginosa (as
high as 25% in one unit, and 19% overall).
Among respiratory isolates collected in the three
primary adult intensive care units, P. aeruginosa
ranked as the ﬁrst or second most prevalent
pathogen, constituting 40% of (non-duplicate)
isolates in one unit, with resistance rates as
high as 65%, 73% and 54% for cephalosporins,
quinolones and meropenem, respectively (46th
International Conference on Antimicrobial
Agents and Chemotherapy, abstracts K-0259
and K-0286). As the clinical implications are sig-
niﬁcant, the selection of appropriate empir-
ical therapy for any infection in which
P. aeruginosa is a likely pathogen is an important
issue, as are efforts to combat resistance, when
considering strategies to improve patient out-
comes.
The purpose of the present analysis was to
investigate the optimisation of meropenem dos-
ing in order to inform decisions concerning
empirical therapy and as a strategy to limit the
development of resistance over time. To do so,
the probability of attaining critical pharmacody-
namic targets for meropenem against nosocomial
isolates of P. aeruginosa was examined. Monte
Carlo simulation was used to account for vari-
ability in microbiological environments and in
the pharmacokinetic properties of the com-
pound. The targets modelled were those that
have been demonstrated to yield bacteriostatic
or bactericidal effects, or that suppress the
ampliﬁcation of more resistant sub-populations
of P. aeruginosa.
MATERIALS AND METHODS
Microbiology
All P. aeruginosa isolates were obtained from hospitalised
patients at Hartford Hospital, an 810-bed tertiary-care hospital
in Hartford, CT, USA, between January and June 2006. During
this period, 208 non-duplicate isolates were collected from
inpatients and were identiﬁed by the hospital microbiology
laboratory. The isolates were obtained from the following
anatomical sites: respiratory tract, n = 107 (51%); wounds,
n = 25 (12%); urine, n = 64 (31%); and other sites, n = 12 (6%).
Susceptibility testing was performed by the Etest method
(AB Biodisk, Solna, Sweden) according to the manufacturer’s
guidelines. Susceptibility to meropenem, and to seven other
antimicrobial agents (cefepime, ceftazidime, ciproﬂoxacin,
gentamicin, levoﬂoxacin, piperacillin–tazobactam and tobra-
mycin), was determined using CLSI interpretative criteria [8].
Pharmacokinetic model
A two-compartment model was used to determine the 24-h
concentration–time proﬁle of meropenem, and to determine
the drug concentration at steady state [9]. Pharmacokinetic
parameters used as input variables included total body
clearance (CLT), volume of the central compartment (Vc), and
the microtransfer rate constants between the central and
peripheral compartments (k12 and k21). These parameters were
used to create probability density functions for use in Monte
Carlo simulations as described below. The mean and standard
deviation used for each of the pharmacokinetic parameters for
meropenem were derived from patients, and were as follows:
for CLT, 14.61 ± 4.98 L ⁄h; for Vc, 13.25 ± 4.59 L; for k12,
1.55 ± 0.57 L; and for k21, 1.48 ± 0.30 L [10]. The fraction of
unbound drug (fu) was also used to create a probability density
function; this was modelled as a range from 0.85 to 0.98, as
indicated in the package insert.
The following intravenous regimens of meropenem were
simulated: 1 g administered every 8 h (q8h); 2 g q8h; and
prolonged infusions of both regimens, 1 g q8h with a 3-h
infusion, and 2 g q8h with a 3-h infusion.
Monte Carlo simulation
A 5000-trial Monte Carlo simulation (Crystal Ball 2000;
Decisioneering, Denver, CO, USA) was conducted using the
pharmacokinetic model in order to determine the probability
of target attainment (PTA) proﬁle for each of the four dosing
regimens of meropenem, using pre-selected measures of
pharmacodynamic exposure. During each of 5000 iterations
of the pharmacodynamic model, different values for CLT, Vc, fu
and k12 and k21 were substituted into the equations in the two-
compartment model—based on the probability density func-
tion for each parameter—to calculate drug concentration for a
series of time-points over the course of the dosing interval
during steady state. Probability density functions were
assumed to follow log-gaussian distributions (using the mean
and standard deviation of each parameter to locate the
distribution), except for fu, which was assumed to follow a
uniform distribution (where each value within the range has
an equal likelihood of occurrence). Thus, the result of each
simulation was 5000 different estimates of drug concentration
at each time-point during steady state for the duration of the
regimen’s dosing interval.
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The simulation results were used to establish the PTA
proﬁle of meropenem at targeted levels of pharmacodynamic
exposure. Pharmacodynamic exposure was analysed in two
ways. First, the portion of the dosing interval during which the
free drug concentration exceeded the MIC (fT>MIC) was
examined relative to each MIC from 0.008 to 128 mg ⁄L for
each of the 5000 trials. A pharmacodynamic index, or target, of
40% of the dosing interval (40% fT>MIC) was used, as this is
considered bactericidal with carbapenems [11]. Separate si-
mulations were conducted at the bacteriostatic target of 20%
fT>MIC. In a second analysis, the ratio of minimum drug
concentration during the steady-state dosing interval to the
MIC (CMIN ⁄MIC) was similarly evaluated relative to each MIC
for the 5000 trials. A CMIN ⁄MIC ratio of ‡6.2 was used to
evaluate monotherapy with meropenem, and a CMIN ⁄MIC
ratio of ‡1.7 was used to model combination therapy with
meropenem and an aminoglycoside. These targets have been
identiﬁed as potentially effective in suppressing the emergence
of certain spontaneous mechanisms of resistance [12].
The results of the Monte Carlo simulations were then used
to calculate the cumulative fraction of response (CFR) for each
dosing regimen at the target index. At each MIC across the
distribution, the PTA at the target was multiplied by the
percentage of isolates found at that MIC; the sum of these
products represents the CFR for the modelled regimen. For the
ﬁrst (bacteriostatic ⁄ bactericidal) analysis, the MIC distribution
for all 208 isolates was included. Since the second analysis
explores the potential for suppressing spontaneous resistance,
only the susceptible isolates (n = 146) were included. Addi-
tionally, differences in bactericidal CFR between isolates
collected at different body sites (respiratory tract, wounds
and urine) were compared using the chi-square test (SigmaStat
for Windows v. 2.03; SPSS Inc., Chicago, IL, USA).
RESULTS
The MIC50, MIC90 and percentage susceptibility
for all 208 isolates of P. aeruginosa are summarised
in Table 1. Overall, meropenem and ciproﬂoxacin
displayed the greatest degree of in-vitro potency,
as indicated by the MIC50 and MIC90 values.
However, the susceptibility data revealed the
presence of many multidrug-resistant organisms
in the population studied. Fig. 1 displays the MIC
distribution of meropenem for the P. aeruginosa
isolates.
Table 2 summarises the CFR for each dosing
regimen of meropenem for the bacteriostatic,
bactericidal and suppressive pharmacodynamic
targets. No regimen displayed an ideal CFR of
>90%; however, CFRs for each scenario were
improved by increasing the dose or by prolonging
the infusion. The ability of meropenem to achieve
the threshold necessary to suppress resistance
when used in combination with an aminoglyco-
side was nearly identical (at a CFR of 79%) to its
ability to achieve bactericidal activity when dosed
at 2 g q8h with a 3-h infusion.
Fig. 2 illustrates the bactericidal PTA of differ-
ent meropenem regimens. Locating the MIC
distribution for a speciﬁc institution on the x-axis
can give a general indication of the ability of each
regimen illustrated to be effectively bactericidal
against a local P. aeruginosa population. Fig. 3
displays the PTA of different regimens of me-
ropenem when bacteriostatic activity is the
desired outcome. This analysis illustrates the fact
that each of the regimens studied has a somewhat
improved likelihood of achieving a bacteriostatic
target compared with a bactericidal target. This
information may be useful when selecting a
Table 1. MIC50, MIC90 and percentage susceptibility for
208 isolates of Pseudomonas aeruginosa
Compound MIC50 MIC90 % Susceptibility
Cefepime 8 32 68
Ceftazidime 2 32 85
Ciproﬂoxacin 0.5 64 62
Gentamicin 4 128 77
Levoﬂoxacin 2 64 57
Meropenem 0.5 64 72
Piperacillin–tazobactam 8 256 89
Tobramycin 1 32 85
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Fig. 1. Distribution of MICs for 208 isolates of Pseudomonas
aeruginosa, displayed as a percentage of total isolates.
Table 2. Cumulative fraction of response (CFR) at bac-
teriostatic, bactericidal and suppressive pharmacodynamic
targets for meropenem against isolates of Pseudomonas
aeruginosa collected from various anatomical sites
Meropenem
regimen
CFR (%) Suppressive CFR (%)
Bacteriostatica Bactericidalb Monotherapeuticc Combinationd
1 g q8h 76.0 71.7 20.9 49.8
2 g q8h 78.8 75.6 34.7 64.2
1 g q8h, 3-h INF 76.9 74.9 32.3 65.2
2 g q8h, 3-h INF 79.4 78.4 50.5 79.0
aCFR calculated at 20% fT>MIC (vs. 208 isolates).
bCFR calculated at 40% fT>MIC (vs. 208 isolates).
cCFR calculated at CMIN ⁄MIC ‡6.2 (vs. 146 susceptible isolates).
dCFR calculated at CMIN ⁄MIC ‡1.7 (vs. 146 susceptible isolates).
INF, infusion; q8h, every 8 h.
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dosing strategy for patients who are not immu-
nocompromised.
Table 2 also reveals that monotherapy with
meropenem was predicted to have <50% prob-
ability of achieving the suppressive threshold
against the population of susceptible isolates,
even with the most aggressive regimen. Figs 4
and 5 illustrate the PTA of different regimens of
meropenem with pharmacodynamic targets of
CMIN ⁄MIC ‡6.2 and ‡1.7, respectively. At an MIC
of 0.5 mg ⁄L, the most aggressive regimen (2 g q8h
with a 3-h infusion) has >80% probability of
achieving the concentration necessary to inhibit
the development of spontaneous resistance in
wild-type P. aeruginosa if combined with an ami-
noglycoside, whereas the same regimen given
alone has <50% probability.
Table 3 summarises the bacteriostatic and bact-
ericidal CFR for each dosing regimen of mero-
penem for isolates collected at speciﬁc body sites.
At the bactericidal target of 40% fT>MIC, CFRs for
all meropenem regimens were signiﬁcantly dif-
ferent among body sites (p 0.005, 0.018, 0.014 and
0.012 for meropenem 1 g q8h, 1 g q8h 3-h infu-
sion, 2 g q8h, and 2 g q8h 3-h infusion, respect-
ively).
DISCUSSION
Infections caused by P. aeruginosa result in signi-
ﬁcant mortality, and the emergence of resistance
has been correlated with a signiﬁcant increase in
morbidity and longer hospital stay [13]. Global
Meropenem PTA at 20% T>MIC
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Fig. 3. Probability of bacteriostatic target attainment using
various regimens of meropenem against Pseudomonas
aeruginosa with a target of 20% fT>MIC (INF, infusion;
q8h, every 8 h; PTA, probability of target attainment).
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Fig. 4. Probability of target attainment (PTA) of various
meropenem regimens when the target is a CMIN ⁄MIC of
‡6.2 (INF, infusion; q8h, every 8 h).
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Fig. 2. Probability of bactericidal target attainment using
various regimens of meropenem, with a target of 40%
fT>MIC (INF, infusion; q8h, every 8 h; PTA, probability of
target attainment).
Meropenem PTA at 1.7 CMIN/MIC
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Fig. 5. Probability of target attainment (PTA) of various
regimens of meropenem when the target is a CMIN ⁄MIC of
‡1.7 (INF, infusion; q8h, every 8 h).
Table 3. Cumulative fraction (CFR) of bacteriostatic and
bactericidal response for meropenem against Pseudomonas
aeruginosa isolates collected from different body sites
Meropenem
regimen
Respiratory
(n = 107)
Wounds
(n = 25)
Urine (n = 64)
Static
CFRa
(%)
Cidal
CFRb
(%)
Static
CFRa
(%)
Cidal
CFRb
(%)
Static
CFRa
(%)
Cidal
CFRb
(%)
1 g q8h 73.1 67.5 89.0 87.5 77.3 73.6
2 g q8h 76.9 72.6 91.4 89.2 78.0 76.6
1 g q8h, 3-h INF 74.2 71.5 89.1 88.2 78.1 76.8
2 g q8h, 3-h INF 77.8 76.3 92.0 90.9 78.1 78.1
aCFR calculated at 20% fT>MIC.
bCFR calculated at 40% fT>MIC.
INF, infusion; q8h, every 8 h.
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surveillance studies of P. aeruginosa have shown
decreased susceptibility against b-lactams, ami-
noglycosides and ﬂuoroquinolones, although sus-
ceptibility to carbapenems remains relatively high
[1,14,15]; however, resistance to carbapenems in
P. aeruginosa is developing [4,5,7,16]. Because of
the continuing decline in susceptibility against the
already limited number of anti-pseudomonal
antibiotics, and because the development of new
antimicrobial agents intended to combat multi-
drug-resistant Gram-negative pathogens is chal-
lenging, it is critical to conserve current antibiotic
resources [17]. The present investigation was
undertaken to examine the potential of using
dose optimisation of meropenem to combat resist-
ance. By selecting regimens that maximise the
probability that the drug will not only provide
microbiological eradication, but also inhibit the
survival of resistant sub-populations, it may be
possible to make judicious use of a still potent
compound.
Four different meropenem regimens were eval-
uated against a population of clinical P. aeruginosa
isolates using the pharmacokinetic and pharmac-
odynamic properties of the drug and Monte Carlo
simulation techniques. The resulting analysis
revealed that the likelihood of achieving bacteri-
cidal thresholds improved when the standard
dose of meropenem was increased from 1 g q8h
to 2 g q8h, and was increased further when either
dose was administered as a prolonged (3-h)
infusion. While bactericidal activity is ideal in
terms of setting a target exposure for drug
performance, bacteriostatic activity can be inform-
ative as a secondary target. In the immunocom-
petent host, bacteriostatic activity may be all that
is necessary to produce the desired clinical
response. For this reason, the parallel analysis
with a pharmacodynamic target of 20% fT>MIC
was conducted. This analysis yielded modest
gains in predicted CFR vs. the bactericidal target.
When choosing empirical therapy, it may also
be important to consider the site of infection.
Predicted CFRs for the isolates studied were
found to differ among body sites, and were
signiﬁcantly higher for isolates collected from
wounds than for the overall P. aeruginosa popu-
lation, although still below the ideal response of a
90% CFR for all but the most aggressive regimen.
Depending upon the MIC proﬁle at a given
institution, it may be possible to treat infections
at some sites without a need to escalate the dose
or infusion time. However, fairly detailed MIC
information (to the site-speciﬁc level) would be
necessary to make this prediction conﬁdently.
Based on a recent study suggesting that it may
be possible to inhibit the spontaneous develop-
ment of certain resistance mechanisms in P. aeru-
ginosa, the proposed suppressive targets were
included in the analysis. These concentrations
were shown in vitro to inhibit the regrowth of sub-
populations of P. aeruginosa that exhibited
reduced susceptibility to meropenem when
compared with the initial population of selected
wild-type isolates [12]. The model predicted that
monotherapy with meropenem would be most
likely to achieve the necessary CMIN ⁄MIC ratio
(6.2) against the susceptible isolates in the popu-
lation when using 2 g q8h as a 3-h infusion, with a
CFR of 50%. The same regimen had a predicted
CFR of 79% when modelled with a target of a
CMIN ⁄MIC ratio of 1.7, which was shown to be the
suppressive threshold when meropenem was
administered in combination with tobramycin.
These data suggest that a large dose of merope-
nem administered as a 3-h infusion, combined
with tobramycin, would provide empirical cover-
age of P. aeruginosa isolates that might be less
susceptible to meropenem. In most clinical set-
tings, drug or dosage de-escalation is undertaken
as soon as culture and susceptibility data become
available. However, based on the present results, it
seems logical to continue the high-dose ⁄prolonged
infusion regimen, in combination with tobramy-
cin, for the duration of therapy, even against
meropenem-susceptible organisms. This regimen
appears to provide the greatest probability not
only of clinical success, but also of preserving the
population of meropenem-susceptible isolates by
preventing the emergence of resistance.
While the model simulates drug behaviour in
critically-ill patients, and incorporates their vari-
ability, it should be stressed that the ability to
achieve any of these pharmacodynamic targets is
affected not only by individual patient character-
istics, but also by the MIC distributions used in
the analysis. As such, differing institutional sus-
ceptibility proﬁles will result in varying probabil-
ities of achieving the desired targets with any
given dosage. It is therefore critical to examine the
MIC distribution of the pathogen of interest at
each individual institution when considering
optimal dosing strategies. Figs 2–5 illustrate the
PTA of different regimens of meropenem at
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various targets and, considered together with
local susceptibility proﬁles, can provide a general
indication of the ability of each regimen to
produce the desired bacteriostatic, bactericidal
or potentially suppressive targets against local
P. aeruginosa populations.
With respect to limiting the development of
resistance, clearly not all mechanisms of resist-
ance can be addressed by a strategy of optimal
dosing. The suppressive thresholds used in the
present study were derived from an in-vitro
model, and no data have been published to date
to support their success in the clinical setting.
Furthermore, the supporting study by Tam et al.
[12] that described these thresholds contains its
own inherent assumptions, which were incorpor-
ated in the present study. Tam et al. [12] also used
a high inoculum of P. aeruginosa (1 · 108 CFU),
which may represent a ‘worst-case’ scenario; it is
certainly possible that in-vivo threshold concen-
trations of meropenem sufﬁcient to suppress
resistance may be lower. In addition, the phar-
macokinetic characteristics of other aminoglyco-
sides may differ from those of tobramycin.
Therefore, it should not be assumed that the
threshold meropenem concentration observed by
Tam et al. [12] would be identical if another
aminoglycoside was used.
Importantly, the present study concerns only a
few of the many (known and unknown) mecha-
nisms by which P. aeruginosa can develop antimi-
crobial resistance. However, if the aim is to
prolong the useful life of a compound, then
inhibiting even a few avenues to mutation can
help to mitigate overall resistance of the patho-
gen, and is thus worthy of pursuit. The results of
the present study suggest that such a strategy is
achievable with reasonable doses of meropenem.
Thus, meropenem 2 g q8h infused over a 3-h
period, used in combination with an aminogly-
coside, appears to be a promising choice for
empirical therapy of P. aeruginosa infections. In
addition, this combination regimen is predicted to
provide a high likelihood of preventing the
spontaneous emergence of meropenem resistance
among susceptible isolates.
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